Omnitura Therapeutics is commercializing Aneustat™, the world’s first multivalent immuno-oncology drug candidate. Our initial disease focus is prostate cancer. Market launch is planned in late 2023 or early 2024.

Aneustat™ is orally delivered and non-toxic. It has been shown to kill cancer cells at all stages of development through apoptosis without developing drug resistance. In combination with FDA approved standard-of-care drugs, Aneustat™ is expected to significantly improve efficacy and quality of life while avoiding or postponing the onset of drug resistance common to standard-of-care drugs.

For cancer patients, Aneustat™ has a unique set of benefits:

Anuestat-logo-3.jpg

  • A new multivalent therapy that addresses the complexity of cancer and overcomes the well-known limitations of single-targeted drugs (e.g., limited effectiveness, susceptibility to the development of drug resistance)

  • Potent Anti-Cancer Activity – proven pre-clinical activity against numerous targets & pathways associated with cancer initiation/progression, including inhibiting metastasis

  • No Drug Resistance – No inherent drug resistance and shown to prevent or delay drug resistance when used in combination with current standard-of-care drugs

  • Synergy – Highly synergetic with current standard-of-care drugs (enhances the efficacy of standard-of-care drugs and in some cases reduces the overall treatment toxicity)

  • Excellent short and long term safety with minimal side effects – a key quality-of-life benefit. Expected to reduce incidences of cancer recurrence, comorbidities and associated secondary costs to patients and society

  • Orally delivered in capsule form – no injections or intrusive delivery methods, reducing cost and the need for visits to healthcare providers

  • Ideal for early stage cancer – Owing to its method of delivery, efficacy and lack of side effects, Aneustat has the potential to be used to intercept and treat early stage cancers as well as late stage cancers. Most current stand-of-care therapies are too toxic for early stage cancer treatment

  • Extensive testing with highly predictive pre-clinical models – indicative of success in human clinical trials & demonstrating tumor shrinkage

  • First clinical trial completed – verified the safety and lack of side-effects in humans, and modulation of key cancer related biomarkers (TGF𝛽, EGF, etc.)

Omnitura invites R&D collaboration, using Aneustat™ as the foundational drug to repurpose blockbuster legacy drugs and allow new patent protection.

Contact us to learn more.